Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons

Neuropsychopharmacology

Volumn 14, Issue 2, 1996, Pages 97-104

  Stockton, Marsha E ^a   Rasmussen, Kurt ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotics; Dopamine; Electrophysiology; Olanzapine; Schizophrenia

Indexed keywords

APOMORPHINE; DOPAMINE; DOPAMINE 1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINERGIC SYSTEM; DRUG STRUCTURE; ELECTROPHYSIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA; VENTRAL ROOT;

EID: 0030040463     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(94)00130-R     Document Type: Article

References (58)

1. Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Holman S, HGAD Olanzapine Study Group (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123
2. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore ND, Tye NC, Seeman P, Wong DT (1996): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
3. Bunney BS (1992): Clozapine: A hypothesized mechanism for its unique clinical profile. Br J Psychiatry 160(suppl. 17):17-21
4. Bunney BS, Aghajanian GK (1974) : A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopaminergic neurons. Life Sci 15:309-318
5. Bunney BS, Aghajanian GK (1975): Antipsychotic drugs and central dopaminergic neurons: A model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In Sudilovsky A, Gershon S, Beer B (eds), Predictability in Psychopharmacology: Preclinical and Clinical Correlations, New York, Raven, pp 225-245
6. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715-1728
7. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973): Dopaminergic neurons: Effects of antipsychotic drugs and amphetamine on single cell activity. J Pharm Exp Ther 185:560-571
8. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
9. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbock R, Tuason V, Klerman G (1987): The risks and benefits of clozapine versus chlorpromazine. J Psychopharmacol 7:377-384
10. Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
11. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486
12. De la Chapelle A, Kari C, Nurminen M, Hernberg S (1977): Clozapine-induced agranulocytosis. Hum Genet 37:183-194
13. Deutch AY (1993): Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: Implications for schizophrenia and Parkinson's disease. J Neural Transm [GenSect] 91:197-221
14. Esposito E, Bunney BS (1988): The effect of acute and chronic treatment with SCH23390 on the spontaneous activity of midbrain dopamine neurons. Eur J Pharmacol 162: 109-113
15. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
16. Fuller RW, Snoddy HD (1992): Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Comm Chem Path Pharm 77:87-93
17. Gewirtz GR, Forman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison J (1994): BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharm 10:37-40
18. Goldstein JM, and Litwin LC (1988a): Spontaneous activity of A9 and A10 dopamine neurons after acute and chronic administration of the selective dopamine D-1 receptor antagonist SCH23390. Eur J Pharmacol 155:175-180
19. Goldstein JM, Litwin LC (1988b): Antipsychotic-like activity of ritanserin following chronic treatment in rats. FASEB 2:A1404
20. 2 antagonist, in electrophysiological tests predictive of anti-psychotic activity. J Pharmacol Exp Ther 249:673-680
21. Goldstein JM, Litwin CL, Sutton EB, Malick JB (1993): Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293-298
22. Grace AA (1919): Phasic versus tonic release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neurosci 41:1-24
23. Grace AA (1992): The depolarization block hypothesis of neuroleptic action: Implications for the etiology and treatment of schizophrenia. J Neural Transm 36:91-131
24. Griffith RW, Saameli K (1975): Clozapine and agranulocytosis. Lancet 2:657
25. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993): Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702-712
26. Joyce JN (1993): The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacology 112:S16-S34
27. Juul Povlsen U, Noring U, Fog R, Gerlach J (1985): Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176-185
28. Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
29. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz DL, Howard A (1988): Clozapine induced agranulocytosis: Non-cross reactivity with psychotropic drugs. J Clin Psychiatry 49:271-277
30. Losonczy MF, Davidson M, Davis KL (1987): The dopamine hypothesis of schizophrenia. In Meltzer HY (ed), Psychopharmacology: The third generation of progress, New York, Raven, pp 715-726
31. 3 receptors. Mol Pharmacol 43:749-754
32. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
33. Meltzer HY (1991): The mechanism of action of novel antipsychotic drugs. Schizophrenia Bull 17:263-287
34. Meltzer HY, Bastani B, Kwon B, Ramirez L, Burnett S, Shapre J (1989): A prospective study of clozapine in treatment-resistant schizophrenic patients. 1. Preliminary report. Psychopharmacology 99(suppl):S68-S72
35. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994): Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiat 35:8-15
36. 3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons. Eur J Pharmacol 209:151-156
37. Minabe Y, Ashby CR, Wang RY (1992): Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons. Eur Neuropsychopharm 2:127-133
38. Moghaddam B, Bunney BS (1993): Depolarization inactivation of dopamine neurons. Terminal release characteristics. Synapse 14:195-200
39. Moore NA, Tye NC, Axton MS, Risius F (1992): The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
40. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
41. 3 mediated control of dopaminergic function. Psychopharmacology 112:S60-S67
42. 3 receptor antagonist, causes a selective decrease in the number of spontaneously active dopaminergic neurons in the rat ventral tegmental area. Eur J Pharmacol 214:13-19
43. 3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 205:113-116
44. Rasmussen K, Stockton ME, Czachura JF, Howbert JJ (1991b): Cholecystokinin (CCK) and schizophrenia: The selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharm 209:135-138
45. Roth BL Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharm Exp Ther 268:1403-1410
46. 4. Neuropsychopharmacology 7:261-284
47. Seeman P (1993): Schizophrenia as a brain disease: The dopamine receptor story. Arch Neurol 50:1093-1095
48. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975): Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 72:4376-4380
49. Skarsfeldt T (1988a): Effect of chronic treatment with SCH23390 and haloperidol on spontaneous activity of dopamine neurons in substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in rats. Eur J Pharmacol 145:239-243
50. Skarsfeldt T (1988b). Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNc and VTA dopamine neurons in rats. Life Sci 42:1037-1044
51. Skarsfeldt T (1992): Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: Acute and repeated treatment. Synapse 10:25-33
52. Skarsfeldt T (1993): Comparison of the effect of substituted benzamides on midbrain dopamine neurons after treatment of rats for 21 days. Eur J Pharmacol 240:269-275
53. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115-118
54. 2 receptors. J Pharmacol Exp Ther 266: 1374-1384
55. Wachtel SR, White FJ (1988): Electrophysiological effects of BMY14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: Acute and chronic studies. J Pharmacol Exp Ther 244:410-416
56. Watchtel SR, White FJ (1992): The effect of continuous and repeated administration of Di dopamine receptor antagonist on midbrain dopamine neurons. Neurochem Int 20:129S-133S
57. Weinberger DR (1987): Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych 44:660-669
58. White FJ, Wang RY (1983): Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057